HealthQuill
Stanford University, along with other researchers, has developed a set of gene delivery systems that can reach different neural cell types in the human brain and spinal cord with exceptional accuracy — a tool which may lead to new gene therapies to treat Parkinson’s, Alzheimer’s and neurogenerative diseases.
Drugs Health Research

Scientists make gene ‘truck’ to unload genetic package in brain, spine

HQ Team May 30, 2025: Stanford University, along with other researchers, has developed a set of gene delivery systems that can reach different.

Read More
Swiss-American Alcon Inc.’s acoltremon ophthalmic solution, Tryptyr, has received a green signal from the US Food and Drug Administration to treat dry eye disease.
Drugs Health Medical

Alcon’s medicine for dry eye disease gets approval from US regulator

HQ Team May 29, 2025: Swiss-American Alcon Inc.’s acoltremon ophthalmic solution, Tryptyr, has received a green signal from the US Food and Drug.

Read More
The US Department of Health and Human Services has terminated a contract awarded to Moderna Inc. for the late-stage development of a bird flu vaccine for humans.
Drugs Health Pharma

US terminates Moderna contract for investigational bird flu vaccine

HQ Team May 29, 2025: The US Department of Health and Human Services has terminated a contract awarded to Moderna Inc. for the.

Read More
More than one million children are at risk of contracting cholera in war-torn Sudan, where 185 deaths have occurred due to the disease since January.
Drugs Health Pharma

A million children at risk of cholera in conflict-hit Sudan: UNICEF says

HQ Team May 29, 2025: More than one million children are at risk of contracting cholera in war-torn Sudan, where 185 deaths have.

Read More
GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract infections after the study achieved its goal on efficacy.
Drugs Health Pharma

GSK, Sepro end trial for oral drug to treat urinary tract infections

 HQ Team May 28, 2025: GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract.

Read More
Schizophrenia is a complex neurobiological disorder that can have long-term effects. Unfortunately, it remains one of the most heavily stigmatised diagnoses in psychiatry.
Health Medical Opinion

A schizophrenic? Warm up to ‘a person with schizophrenia’ 

By Aparna S. May 28, 2025: World Schizophrenia Day was observed recently to encourage society and mental health professionals to re-evaluate how we.

Read More
The US drug regulator halted Rocket Pharmaceuticals Inc.’s investigational gene therapy for Danon disease after a patient died due to an infection, according to a company statement.
Drugs Health Pharma

FDA halts Rocket’s Danon disease mid-stage therapy as patient dies

HQ Team May 28, 2025: The US drug regulator halted Rocket Pharmaceuticals Inc.’s investigational gene therapy for Danon disease after a patient died.

Read More
Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.
Drugs Health Pharma

Eli Lilly to buy SiteOne to grab test inhibitor to treat chronic pain

HQ Team May 28, 2025: Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor.

Read More
The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Drugs Medical Pharma

GSK Plc’s drug to treat COPD gets clearance from US drug regulator

HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive.

Read More
Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases as well as traumatic injury.
Uncategorized

‘Mailman’ gene-editing tool carries molecule to exact ‘zip code’

HQ Team May 24, 2025: Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases.

Read More